You are here

  • Home
  • Archive
  • Volume 70, Issue 6
  • Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Spiera RF, Gordon JK, Mersten JN, et al
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
Annals of the Rheumatic Diseases 2011;70:1003-1009.